Hovione Passes FDA Inspection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Hovione Passes FDA Inspection



Untitled Document

Hovione's plant in Loures, Portugal has passed a GMP and postmarket approval inspection by FDA. The inspection lasted five days as initially planned, and began on Sept. 23, 2013 was concluded on Sept. 27, 2013. At the closing meeting, the inspector was satisfied the company's GMP system, and the inspection was sucessful.

Hovione’s five plants were the object of 12 inspections in the last 18 months. These inspections were performed by health authorities, including five by FDA, three by the Portuguese Health Authority, one by the Irish Medicines Board, one by Korean health authorities, and two by China’s health authority.

Source: Hovione

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here